Published in Mol Cancer on January 07, 2003
Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res (2010) 1.48
Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer (2011) 1.45
Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer (2008) 1.26
Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer (2007) 1.23
14-3-3sigma Modulates pancreatic cancer cell survival and invasiveness. Clin Cancer Res (2008) 1.17
Down-regulation of survivin expression by small interfering RNA induces pancreatic cancer cell apoptosis and enhances its radiosensitivity. World J Gastroenterol (2006) 1.10
Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Res (2009) 1.02
Ellagic acid induces apoptosis through inhibition of nuclear factor kappa B in pancreatic cancer cells. World J Gastroenterol (2008) 1.02
Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother Pharmacol (2009) 0.98
Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer. J Clin Pathol (2006) 0.97
Ginkgo biloba extract kaempferol inhibits cell proliferation and induces apoptosis in pancreatic cancer cells. J Surg Res (2008) 0.93
Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells. Drug Des Devel Ther (2015) 0.92
REACTIN: regulatory activity inference of transcription factors underlying human diseases with application to breast cancer. BMC Genomics (2013) 0.91
Establishment of three-dimensional cultures of human pancreatic duct epithelial cells. Biochem Biophys Res Commun (2007) 0.89
Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer. Mol Cancer Ther (2014) 0.83
Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Mol Cancer (2013) 0.81
Anti-neoplastic efficacy of Haimiding on gastric carcinoma and its mechanisms. World J Gastroenterol (2004) 0.80
Genomic analysis of pterostilbene predicts its antiproliferative effects against pancreatic cancer in vitro and in vivo. J Gastrointest Surg (2012) 0.80
ZIP4 confers resistance to zinc deficiency-induced apoptosis in pancreatic cancer. Cell Cycle (2014) 0.78
miR-134: A Human Cancer Suppressor? Mol Ther Nucleic Acids (2016) 0.77
Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus. Virology (2014) 0.77
Stable transfection of extrinsic Smac gene enhances apoptosis-inducing effects of chemotherapeutic drugs on gastric cancer cells. World J Gastroenterol (2005) 0.77
Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines. J Virol (2014) 0.76
The role of apoptosis in the pathology of pancreatic cancer. Cancers (Basel) (2010) 0.75
Thymoquinone Promotes Pancreatic Cancer Cell Death and Reduction of Tumor Size through Combined Inhibition of Histone Deacetylation and Induction of Histone Acetylation. Adv Prev Med (2016) 0.75
The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer. J Exp Clin Cancer Res (2017) 0.75
The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2. DNA Cell Biol (2015) 0.75
Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell (1997) 24.57
The clonal evolution of tumor cell populations. Science (1976) 24.39
Mitochondria and apoptosis. Science (1998) 23.41
Caspases: enemies within. Science (1998) 19.45
Cellular survival: a play in three Akts. Genes Dev (1999) 17.05
The Bcl-2 protein family: arbiters of cell survival. Science (1998) 16.08
Apoptosis by death factor. Cell (1997) 14.42
An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science (1996) 13.87
The Fas death factor. Science (1995) 13.81
NF-kappaB at the crossroads of life and death. Nat Immunol (2002) 12.98
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med (1997) 12.65
Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell (2000) 11.90
Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature (1995) 11.61
NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer (2002) 11.39
The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell (1991) 10.96
Two CD95 (APO-1/Fas) signaling pathways. EMBO J (1998) 10.42
IAP family proteins--suppressors of apoptosis. Genes Dev (1999) 9.96
Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell (1996) 9.93
Inhibition of death receptor signals by cellular FLIP. Nature (1997) 9.58
Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell (1993) 9.06
Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell (2000) 8.69
Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (1998) 8.60
X-linked IAP is a direct inhibitor of cell-death proteases. Nature (1997) 8.26
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A (1999) 7.88
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci U S A (1997) 7.25
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol (1998) 6.38
Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer (2002) 5.87
The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell (1995) 5.50
Proteases to die for. Genes Dev (1998) 5.43
IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res (1998) 5.41
AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A (1992) 5.24
Cancer statistics, 1997. CA Cancer J Clin (1997) 5.22
An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol (1993) 5.15
Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med (2000) 4.40
Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science (1997) 4.19
Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood (1992) 4.14
The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol (2001) 3.66
Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res (1998) 3.63
Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol (2001) 3.63
Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol (1998) 3.32
The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol (2000) 3.12
FAP-1: a protein tyrosine phosphatase that associates with Fas. Science (1995) 3.06
The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res (2001) 3.02
Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell (2002) 3.02
FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity (2000) 2.99
Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood (1993) 2.96
An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. J Virol (1994) 2.95
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch (2001) 2.73
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene (2002) 2.66
Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J Biol Chem (1999) 2.65
A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem (1998) 2.64
Transforming growth factor alpha. Cell (1988) 2.56
Regulation of cell proliferation by Smad proteins. J Cell Physiol (2002) 2.55
Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest (1992) 2.54
Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. J Exp Med (2000) 2.51
FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol (2001) 2.39
New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J (1999) 2.39
Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res (1998) 2.38
Cleavage of lamin A by Mch2 alpha but not CPP32: multiple interleukin 1 beta-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. Proc Natl Acad Sci U S A (1996) 2.31
Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol (2002) 2.27
Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet (1998) 2.08
Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci U S A (1998) 2.04
Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene (1998) 2.03
Human lung carcinomas express Fas ligand. Cancer Res (1997) 1.94
Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells (1998) 1.94
Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem (2000) 1.91
Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res (1995) 1.89
The central effectors of cell death in the immune system. Annu Rev Immunol (1999) 1.87
Protein kinase D: an intracellular traffic regulator on the move. Trends Cell Biol (2002) 1.81
TGF beta 1 inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: transcriptional activation of I kappa B alpha. Immunity (1996) 1.81
Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am (1998) 1.74
Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer (2001) 1.73
CASH, a novel caspase homologue with death effector domains. J Biol Chem (1997) 1.72
Mechanisms of TGF-beta-mediated apoptosis. Cell Tissue Res (2001) 1.72
Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res (2000) 1.69
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene (2000) 1.69
An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem (2002) 1.65
Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem (2002) 1.62
KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res (1996) 1.59
Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis. Cancer Biol Ther (2002) 1.58
Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg (1994) 1.57
Apoptosis and carcinogenesis. Eur J Cell Biol (1997) 1.48
Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res (2001) 1.47
Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene (2001) 1.46
MRIT, a novel death-effector domain-containing protein, interacts with caspases and BclXL and initiates cell death. Proc Natl Acad Sci U S A (1997) 1.44
Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res (2001) 1.44
Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int J Cancer (2002) 1.39
Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology (2002) 1.38
Apoptotic pathways: involvement of lysosomal proteases. Biol Chem (2002) 1.38
Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem (2002) 1.36
Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg (2002) 1.35
Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res (1998) 1.28
Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys (2002) 1.28
Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem Pharmacol (2002) 1.25
The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc (2001) 1.24
Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res (1998) 1.21
The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem Biophys Res Commun (2002) 1.20
Tumor necrosis factor alpha induces the expression of transforming growth factor alpha and the epidermal growth factor receptor in human pancreatic cancer cells. Proc Natl Acad Sci U S A (1993) 1.20
Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res (2000) 1.17
A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch (2003) 2.53
Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res (2007) 2.21
Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res (2004) 2.19
Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia (2004) 2.08
Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene (2005) 1.89
Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int (2007) 1.67
Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res (2008) 1.64
Dexamethasone reduces tumor recurrence and metastasis after pancreatic tumor resection in SCID mice. Cancer Biol Ther (2008) 1.53
Genetic and functional identification of the likely causative variant for cholesterol gallstone disease at the ABCG5/8 lithogenic locus. Hepatology (2013) 1.53
Ganciclovir prodrug therapy is effective in a murine xenotransplant model of human lung cancer. Ann Thorac Surg (2002) 1.49
Detection of occult tumor cells in lymph nodes from bladder cancer patients by MUC7 nested RT-PCR. Eur Urol (2004) 1.44
Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer (2004) 1.43
Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. J Cell Mol Med (2008) 1.33
Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma. Int J Cancer (2011) 1.28
Investigation of the colorectal cancer susceptibility region on chromosome 8q24.21 in a large German case-control sample. Int J Cancer (2009) 1.25
Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res (2005) 1.21
PKCmu prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells. Oncogene (2003) 1.21
Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer (2014) 1.12
CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. FASEB J (2005) 1.11
Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol (2010) 1.09
Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma--epigenetic downregulation of caspases. Int J Cancer (2008) 1.08
Examination of apoptosis signaling in pancreatic cancer by computational signal transduction analysis. PLoS One (2010) 1.07
Epicatechin gallate and catechin gallate are superior to epigallocatechin gallate in growth suppression and anti-inflammatory activities in pancreatic tumor cells. Cancer Sci (2011) 1.04
Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer (2003) 1.03
Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17. Int J Cancer (2013) 1.03
Dual regulation of telomerase activity through c-Myc-dependent inhibition and alternative splicing of hTERT. J Cell Sci (2002) 1.03
Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells. J Biol Chem (2002) 1.02
CEACAM1 modulates epidermal growth factor receptor--mediated cell proliferation. J Clin Invest (2004) 1.02
Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer. J Nucl Med (2008) 1.01
Lymphatic spread of ductal pancreatic adenocarcinoma is independent of lymphangiogenesis. J Pathol (2005) 1.01
Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma. Eur J Cell Biol (2010) 0.99
TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. J Mol Med (Berl) (2010) 0.99
Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. J Cancer Res Clin Oncol (2005) 0.97
Transforming growth factor-beta (TGF-beta) type I receptor/ALK5-dependent activation of the GADD45beta gene mediates the induction of biglycan expression by TGF-beta. J Biol Chem (2004) 0.95
Microarray-based gene expression profiling in pancreatic ductal carcinoma: status quo and perspectives. Int J Colorectal Dis (2004) 0.94
Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Hepatobiliary Pancreat Dis Int (2014) 0.93
Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells. Cell Signal (2007) 0.93
Expression of lymphangiogenic factors and evidence of intratumoral lymphangiogenesis in pancreatic endocrine tumors. Am J Pathol (2004) 0.92
Investigation of innate immunity genes CARD4, CARD8 and CARD15 as germline susceptibility factors for colorectal cancer. BMC Gastroenterol (2009) 0.91
Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. Int J Cancer (2013) 0.91
Regulation of biglycan gene expression by transforming growth factor-beta requires MKK6-p38 mitogen-activated protein Kinase signaling downstream of Smad signaling. J Biol Chem (2003) 0.90
Vascular endothelial growth factor mediated angiogenic potential of pancreatic ductal carcinomas enhanced by hypoxia: an in vitro and in vivo study. Int J Cancer (2002) 0.90
Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. Histopathology (2013) 0.90
Adhesion and Rac1-dependent regulation of biglycan gene expression by transforming growth factor-beta. Evidence for oxidative signaling through NADPH oxidase. J Biol Chem (2005) 0.89
O-acetylation and de-O-acetylation of sialic acids in human colorectal carcinoma. Eur J Biochem (2004) 0.89
The potential molecular mechanism of overexpression of uPA, IL-8, MMP-7 and MMP-9 induced by TRAIL in pancreatic cancer cell. Hepatobiliary Pancreat Dis Int (2008) 0.88
Myofibroblast-induced tumorigenicity of pancreatic ductal epithelial cells is L1CAM dependent. Carcinogenesis (2011) 0.88
Near-infrared molecular imaging of tumors via chemokine receptors CXCR4 and CXCR7. Clin Exp Metastasis (2011) 0.88
Detection and clinical implications of minimal residual disease in gastro-intestinal cancer. Langenbecks Arch Surg (2005) 0.86
The diversity between pancreatic head and body/tail cancers: clinical parameters and in vitro models. Hepatobiliary Pancreat Dis Int (2013) 0.86
Paraneoplastic leukemoid reaction and rapid progression in a patient with malignant melanoma: establishment of KT293, a novel G-CSF-secreting melanoma cell line. Cancer Biol Ther (2005) 0.85
Systematic identification and validation of candidate genes for detection of circulating tumor cells in peripheral blood specimens of colorectal cancer patients. Int J Oncol (2008) 0.84
TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells. BMC Cancer (2014) 0.84
Adjuvant treatment of pancreatic carcinoma in a clinically adapted mouse resection model. Pancreatology (2006) 0.83
Superiority of extended neoadjuvant chemotherapy with gemcitabine in pancreatic cancer: a comparative analysis in a clinically adapted orthotopic xenotransplantation model in SCID beige mice. Cancer Biol Ther (2007) 0.83
Characterization of the sialate-7(9)-O-acetyltransferase from the microsomes of human colonic mucosa. Biol Chem (2002) 0.83
Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice. Anticancer Res (2010) 0.83
Polymorphisms in the mitochondrial oxidative phosphorylation chain genes as prognostic markers for colorectal cancer. BMC Med Genet (2012) 0.82
Concerted deregulations of multiple apoptosis-controlling genes in pancreatic carcinoma cells. Ann N Y Acad Sci (2003) 0.82
Gemcitabine-mediated apoptosis is associated with increased CD95 surface expression but is not inhibited by DN-FADD in Colo357 pancreatic cancer cells. Cancer Lett (2005) 0.82
Wortmannin inhibits growth of human non-small-cell lung cancer in vitro and in vivo. Langenbecks Arch Surg (2002) 0.81
Detection and prognostic impact of disseminated tumor cells in pancreatic carcinoma. Pancreatology (2002) 0.81
Disseminated tumor cells in the bone marrow negatively influence survival after resection of colorectal liver metastases. Ann Surg Oncol (2012) 0.81
Integrins and their ligands are expressed in non-small cell lung cancer but not correlated with parameters of disease progression. Virchows Arch (2013) 0.81
Establishment of a novel orthotopic xenograft model of human gallbladder carcinoma. Clin Exp Metastasis (2007) 0.81
Influence of tumor-associated E-cadherin mutations on tumorigenicity and metastasis. Carcinogenesis (2003) 0.81
TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells. Hepatobiliary Pancreat Dis Int (2013) 0.80
Antitumor activity of ALK1 in pancreatic carcinoma cells. Int J Cancer (2007) 0.80
Expression of L amino acid transport system 1 and analysis of iodine-123-methyltyrosine tumor uptake in a pancreatic xenotransplantation model using fused high-resolution-micro-SPECT-MRI. Hepatobiliary Pancreat Dis Int (2011) 0.79
Investigation of cholangiocarcinoma associated NKG2D polymorphisms in colorectal carcinoma. Int J Cancer (2008) 0.79
Correlation between metastatic potential and variants from colorectal tumor cell line HT-29. World J Gastroenterol (2003) 0.79
Prowling wolves in sheep's clothing: the search for tumor stem cells. Biol Chem (2008) 0.79
Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma. Int J Cancer (2012) 0.78
Terminally modified oligodeoxynucleotides directed against p53 in an orthotopic xenograft model: a novel adjuvant treatment strategy for pancreatic ductal carcinoma. Pancreas (2004) 0.78
Association study identifying polymorphisms in CD47 and other extracellular matrix pathway genes as putative prognostic markers for colorectal cancer. Int J Colorectal Dis (2012) 0.78
Resistance developing after long-term ganciclovir prodrug treatment in a preclinical model of NSCLC. Anticancer Res (2004) 0.77
Application of ex vivo micro-computed tomography for assessment of in vivo fluorescence and plain radiographic imaging for monitoring bone metastases and osteolytic lesions. J Bone Miner Metab (2011) 0.77
Validation and comparison of anti-αvβ3 and anti-αvβ5 rabbit monoclonal versus murine monoclonal antibodies in four different tumor entities. Appl Immunohistochem Mol Morphol (2013) 0.77
Establishment and characterization of primary cell lines of squamous cell carcinoma of the penis and its metastasis. J Urol (2012) 0.77
Assessment of anti-inflammatory tumor treatment efficacy by longitudinal monitoring employing sonographic micro morphology in a preclinical mouse model. BMC Med Imaging (2011) 0.77
Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways. J Carcinog (2006) 0.76
Preclinical evaluation of sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases. BMC Cancer (2013) 0.75
Retroviral endostatin gene transfer inhibits growth of human lung cancer in a murine orthotopic xenotransplant model. Langenbecks Arch Surg (2003) 0.75
Gene transfer and expression of enhanced green fluorescent protein in variant HT-29c cells. World J Gastroenterol (2003) 0.75
Stable expression of temperature-sensitive p53: a suitable model to study wild-type p53 function in pancreatic carcinoma cells. Oncol Rep (2006) 0.75
Efficient dose-dependent and time-dependent protein transduction of pancreatic carcinoma cells in vitro and in vivo using purified VP22-EGFP fusion protein. J Mol Med (Berl) (2003) 0.75
Pancreatic cancer--are there new treatment options? Adv Exp Med Biol (2006) 0.75
Characterisation of a novel matrix metalloproteinase inhibitor on pancreatic adenocarcinoma cells in vitro and in an orthotopic pancreatic cancer model in vivo. Int J Oncol (2008) 0.75
A modified random oligonucleotide-based combination therapy for adjuvant treatment of pancreatic ductal adenocarcinoma. Int J Oncol (2006) 0.75
Following the death TRAIL to hunt down tumor cells: translating programmed cell death signaling mechanisms into clinical practice. Results Probl Cell Differ (2009) 0.75
Silvalactam, a 24-membered macrolactam antibiotic produced by Streptomyces sp. Tü 6392*. J Antibiot (Tokyo) (2012) 0.75
Lymphatic spread in squamous cell carcinoma of the penis is independent of elevated lymph vessel density. BJU Int (2009) 0.75
Target gene discovery for novel therapeutic agents in cancer treatment. Methods Mol Biol (2010) 0.75
Emerging therapeutic targets and agents for pancreatic cancer therapy--where are we and where we have to go? Anticancer Agents Med Chem (2011) 0.75
Characterisation of FAP-1 expression and CD95 mediated apoptosis in the A818-6 pancreatic adenocarcinoma differentiation system. Differentiation (2011) 0.75
The role of protein kinases in pancreatic carcinogenesis. Clin Chim Acta (2007) 0.75